{
    "2019-02-24": [
        [
            {
                "time": "",
                "original_text": "带量采购愈推进，CRO/创新主线愈受益｜【光大医药·周报】",
                "features": {
                    "keywords": [
                        "带量采购",
                        "CRO",
                        "创新主线",
                        "光大医药",
                        "周报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "508亿吸并白药控股云南白药重组“三易其稿”",
                "features": {
                    "keywords": [
                        "508亿",
                        "吸并",
                        "白药控股",
                        "云南白药",
                        "重组",
                        "三易其稿"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}